PRC vaccine leader AIM Vaccine (06660.HK) announced on February 26 that its self-developed mRNA RSV (Respiratory Syncytial Virus) vaccine has recently received clinical trial approval from the U.S ...
Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for ...
Sanofi has various mRNA vaccines in development for infectious diseases, including respiratory syncytial virus (RSV), influenza, and meningitis, among others. Sanofi’s global head of vaccine ...
Total company revenue fell from a peak of $19.3 billion in 2022 to $3.2 billion for the full year ended Dec. 31, 2024. For ...
A new study by Fikrig and other researchers, published Wednesday in Science Translational Medicine, uses a powerful ...
Population-based analyses of new vaccination programmes provide robust real-world evidence for post-licensure vaccine ...
the mRNA shingles vaccine and the mRNA RSV vaccine. In just one month, AIM has leveraged its independently innovated mRNA technology platform to deliver two major products, both of which have received ...
A vaccine kept patients free of pancreatic cancer for years, yet new reports say the NIH is advising against mentioning mRNA tech in grants.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback